Key result
Admission type I interferon activation and 2-gene signature independently predict higher 5-year major cardiovascular events after AMI.
Why the study?
Does early activation of type I interferon-related transcriptional programs at hospital admission identify a post-AMI immunophenotype associated with 5-year major adverse cardiovascular events?
Cohort
Does early activation of type I interferon-related transcriptional programs at hospital admission identify a post-AMI immunophenotype associated with 5-year major adverse cardiovascular events?
Early activation of type I interferon signaling, captured by a 2-gene blood signature (IFNAR2, IFI35) at AMI admission, defines a distinct immunophenotype that independently predicts 5-year cardiovascular risk beyond classical inflammatory markers.
Answers are grounded in this paper and cite their sources.
Should not yet change post-MI risk stratification; leaves open interferon signatures for precision prognostication in future trials.
Persistent inflammation contributes to residual cardiovascular risk after acute myocardial infarction (AMI), yet biomarkers capturing maladaptive immune programs remain limited. We investigated whether early activation of type I interferon (IFN)-related transcriptional programs identifies a distinct immune phenotype associated with long-term outcomes. Peripheral-blood RNA sequencing was performed at hospital admission in a prospective AMI cohort, with 5-year follow-up for major adverse cardiovascular events. Transcriptomic and pathway analyses revealed coordinated activation of type I IFN signaling in patients with adverse outcomes. Type I IFN response was independently associated with long-term risk after adjustment for clinical variables, whereas classical inflammatory and inflammation-related transcriptomic markers did not retain significance. A minimal 2-gene signature (IFNAR2, IFI35) captured this immune state, discriminated high- and low-risk patients, and remained independently prognostic in time-to-event analyses. These findings define a distinct post-AMI immunophenotype and support type I IFN signaling as a biologically grounded axis for precision risk stratification.
No takes yet. Share an insight, caveat, or question.
Piacentini et al. (2026) conducted a cohort in Acute myocardial infarction (AMI). Early activation of type I interferon (IFN)-related transcriptional programs (including a 2-gene signature of IFNAR2 and IFI35) vs. Patients without type I IFN signaling activation / classical inflammatory and inflammation-related transcriptomic markers was evaluated on Major adverse cardiovascular events (MACE) over 5-year follow-up. Type I interferon response activation at AMI admission and a minimal 2-gene signature (IFNAR2, IFI35) independently predicted 5-year major adverse cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: